Triple

T7031287
Position Surface form Disambiguated ID Type / Status
Subject 340B Drug Pricing Program E163275 entity
Predicate relatedProgram P37 FINISHED
Object Medicaid Drug Rebate Program
The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
E637326 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Medicaid Drug Rebate Program | Statement: [340B Drug Pricing Program, relatedProgram, Medicaid Drug Rebate Program]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Medicaid Drug Rebate Program
Context triple: [340B Drug Pricing Program, relatedProgram, Medicaid Drug Rebate Program]
  • A. 340B Drug Pricing Program
    The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
  • B. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
    The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
  • C. Prescription Drug User Fee Act of 1992
    The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
  • D. Medicare Part D
    Medicare Part D is the U.S. federal program that provides outpatient prescription drug coverage to Medicare beneficiaries through private insurance plans.
  • E. Center for Program Integrity
    The Center for Program Integrity is a division within the Centers for Medicare & Medicaid Services responsible for preventing fraud, waste, and abuse in federal health care programs and ensuring proper payment and program compliance.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Medicaid Drug Rebate Program
Triple: [340B Drug Pricing Program, relatedProgram, Medicaid Drug Rebate Program]
Generated description
The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Medicaid Drug Rebate Program
Target entity description: The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
  • A. 340B Drug Pricing Program
    The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
  • B. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
    The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
  • C. Prescription Drug User Fee Act of 1992
    The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
  • D. Medicare Part D
    Medicare Part D is the U.S. federal program that provides outpatient prescription drug coverage to Medicare beneficiaries through private insurance plans.
  • E. Center for Program Integrity
    The Center for Program Integrity is a division within the Centers for Medicare & Medicaid Services responsible for preventing fraud, waste, and abuse in federal health care programs and ensuring proper payment and program compliance.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c6885d691c81908cf7d31083113886 completed March 27, 2026, 1:38 p.m.
NER Named-entity recognition batch_69c6e20ee1208190811be10a84e7d8a4 completed March 27, 2026, 8:01 p.m.
NED1 Entity disambiguation (via context triple) batch_69c775980920819081d31b8d2843fb3d completed March 28, 2026, 6:30 a.m.
NEDg Description generation batch_69c77aa1c704819088a9561ac55f9037 completed March 28, 2026, 6:52 a.m.
NED2 Entity disambiguation (via description) batch_69c77b082f3c8190a649297ce0f816bb completed March 28, 2026, 6:54 a.m.
Created at: March 27, 2026, 2:35 p.m.